News

 

NorthSea Therapeutics appoints Morris J. Birnbaum to the Board

Former Pfizer Internal Medicine CSO joins the Boardas an independent board member   Amsterdam, The Netherlands, 21 December 2022 – NorthSea Therapeutics B.V. (‘NST’), a  biotech company developing novel and innovative strategies for the treatment of...

NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)

Naarden, The Netherlands, 25 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, today announces dosing of the first patient with icosabutate in a phase 2b dose ranging study (‘ICONA’).

“We believe icosabutate has the potential to impact the lives of millions of NASH patients globally”
Rob de Ree

Chief Executive Officer, NorthSea Therapeutics

Voor meer informatie:

info@northseatherapeutics.com

+31 (0) 35 760 65 05